By modifying the drug release characteristics, significant therapeutic benefits can be achieved, such as improved efficacy of the therapeutic agent, reduced adverse effects, optimization of the dosing scheme, and overall improvement in patient compliance. There are numerous approaches for modified release, each with its own benefits and drawbacks. This webinar will present PVA, a fully-synthetic polymer, for optimized sustained release matrix formulations. Combining robust and reliable gel-forming behavior with optimized tableting properties, PVA provides solutions for the most challenging sustained-release formulations.
In this webinar, you will learn:
- How the gel-formation properties of PVA introduce sustained release
- Why compatibility with direct compression leads to simplified formulations
- That PVA can provide flexibility in sustained release formulation development
Speaker
Gudrun Birk, Ph.D.
MilliporeSigma
Head of Controlled Release
Gudrun is a pharmacist by education and has been with MilliporeSigma since April 2014. Within the R&D organization, she and her team focus on the development of innovative new excipients and functional excipients systems for solid oral dosage forms. She presents research results at scientific conferences and in publications as well as provides customers with guidance and support for their unique formulation challenges. Gudrun studied pharmacy at the University of Freiburg, Germany, and holds a Ph.D. from Ludwig Maximilian University of Munich, Germany.
Pharma and biopharma manufacturing
- Solid Formulation Strategies
Duration:58min
Language:English
Session 1:presented August 20, 2020
To continue reading please sign in or create an account.
Don't Have An Account?